Optimal Thiotepa Exposure Is Associated with Improved Rejection and Non-Relapse Mortality in Pediatric Patients Undergoing Alpha-Beta-T-cell/CD19-Depleted Haploidentical HCT for Hematologic Malignancy
Key Points
Improved non-relapse mortality is associated with optimal thiotepa exposure in pediatric patients undergoing haploidentical HCT.
Research indicates a significant linkage between thiotepa dosage and better rejection rates, providing key insights for treatment.
Assessment of treatment outcomes highlights the importance of thiotepa during haploidentical HCT for hematologic malignancy.
Findings suggest that optimized thiotepa dosing could enhance recovery prospects, warranting further exploration in clinical settings.
Optimal Thiotepa Exposure Is Associated with Improved Rejection and Non-Relapse Mortality in Pediatric Patients Undergoing Alpha-Beta-T-cell/CD19-Depleted Haploidentical HCT for Hematologic Malignancy | Synapse